ArticlebioRxiv : the preprint server for biology2026
A statistical framework for disease classification with scRNA-Seq Data.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Motivation: Bulk RNA-sequencing based disease classification obscures cell-type specific signals by aggregating gene expression across heterogeneous tissues. Although single-cell RNA-seq tackles this limitation, summarizing and deriving patient-level predictors while retaining biological interpretability remains challenging. Standard sparse methods, such as lasso, often select arbitrary scattered gene sets without leveraging the underlying cell type structures revealed by single-cell data. Results: We introduce a two-stage statistical framework for interpretable patient-level disease classification from single-cell data. We first construct a gene-by-cell-type pseudobulk matrix that summarize single-cell expression for each patient. We then fit a multinomial logistic regression model with sparse group lasso penalty, inducing sparsity at both the cell type and gene levels. Across datasets of systemic lupus erythematosus, COVID-19, and colorectal cancer, our framework either matched or outperformed lasso and random forest baselines. Importantly, our models recovered biologically coherent, cell-type specific gene signatures consistent with known disease mechanisms, demonstrating improved interpretability without sacrificing predictive accuracy. Availability: The scSGL R package implementing the Sparse Group Lasso classification frame-work described in this paper is available at https://github.com/zhiweixiao/scSGL (version 0.99.1). Code to reproduce the actual cross-validation, model fitting, and prediction analyses on the three datasets reported here is available at https://github.com/zhiweixiao/scSGL-manuscript.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.